Opportunity Information: Apply for PAR 21 055
The National Institutes of Health (NIH) funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" (Funding Opportunity Number PAR-21-055) supports investigator-initiated research that adds a focused mechanistic study onto an already existing, ongoing clinical project. The main idea is to leverage active clinical studies, cohorts, or trials that are already enrolling participants or collecting samples and data, and then use that existing infrastructure to answer deeper "how and why" questions about underlying biological, behavioral, or other mechanisms relevant to human health. Because the funding mechanism is an R01 research project grant, the application is expected to propose a well-developed, hypothesis-driven ancillary study with clear aims, strong scientific rationale, and a feasible plan that fits alongside the parent clinical project without disrupting it.
A key feature of this opportunity is the "Clinical Trial Not Allowed" designation. That means applicants cannot propose a new clinical trial as the ancillary study itself. In practical terms, the proposed work should not involve prospectively assigning human participants to an intervention or condition to evaluate the effect on health-related outcomes. Instead, the grant is meant to fund mechanistic investigations that take advantage of participants, measurements, clinical data, or biospecimens being collected as part of an existing clinical project. Typical examples of what this kind of mechanism often supports include laboratory analyses of stored or newly collected biospecimens, additional biomarker assays, immunologic or genomic profiling, advanced imaging analyses, physiologic or pharmacodynamic assessments, or other mechanistic measurements that can be layered onto the parent study. The ancillary study should be clearly connected to the parent project, scientifically additive (not duplicative), and realistically implementable within the timelines and operational constraints of the ongoing clinical work.
This opportunity sits in the NIH health research portfolio and is listed under CFDA number 93.846. It is categorized as a discretionary grant program and uses the grant funding instrument. While the excerpted source data does not list an expected number of awards, it does provide an award ceiling of $300,000, which signals a budget expectation or maximum for the opportunity as presented in the dataset (applicants would still need to follow the specific budget rules and guidance in the full announcement and NIH policies). The original closing date shown in the source data is 2022-11-21, and the opportunity record creation date is 2020-10-22. Since NIH opportunities can be reissued, updated, or replaced over time, anyone considering submission would typically verify the current status and active receipt dates in the live NIH posting and related notices.
Eligibility is broad and includes many common U.S. applicant organization types. Eligible applicants listed include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofit organizations both with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses. The announcement also explicitly highlights additional eligible applicant categories, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal government agencies, regional organizations, and U.S. territories or possessions. These categories underline NIH's openness to a wide range of institutions capable of carrying out rigorous mechanistic research in connection with ongoing clinical studies.
At the same time, the opportunity includes important restrictions related to non-U.S. entities and components. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic (non-U.S.) foreign institutions are stated as not eligible to apply, and non-domestic components of U.S. organizations are also not eligible to apply. However, foreign components are allowed as defined in the NIH Grants Policy Statement. In NIH terms, that generally means a U.S. applicant organization can include a foreign component in the project when it is scientifically justified and appropriately managed and disclosed, even though a foreign institution cannot serve as the primary applicant. This distinction matters for projects that may require specialized assays, unique populations, or collaborative resources outside the United States, while keeping the primary award and accountability with an eligible U.S.-based applicant.
Overall, PAR-21-055 is designed for researchers who already have access to an active clinical project and want to use that opportunity to do deeper mechanistic science that would be difficult or inefficient to run as a standalone study. The successful application would typically make a clear case that the ancillary mechanistic work is tightly integrated with the ongoing clinical project, provides high value for understanding disease processes or treatment responses, stays within the "no clinical trial" boundary, and can be completed using a realistic plan for coordination, data and specimen access, human subjects protections, and analytical rigor.Apply for PAR 21 055
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
- This funding opportunity was created on 2020-10-22.
- Applicants must submit their applications by 2022-11-21. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the NIH funding opportunity PAR-21-055?
PAR-21-055 is an NIH Funding Opportunity Announcement titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)." It supports investigator-initiated R01 applications that propose a focused mechanistic ancillary study that can be added onto an already existing, ongoing clinical project.
What is the purpose of this grant opportunity?
The purpose is to leverage active clinical studies, cohorts, or trials that are already enrolling participants or collecting samples and data, and use that existing infrastructure to answer deeper mechanistic "how and why" questions related to human health (for example, biological, behavioral, or other mechanisms).
What does "mechanistic ancillary study" mean in this context?
In this context, a mechanistic ancillary study is a hypothesis-driven research project that layers additional mechanistic measurements or analyses onto an ongoing parent clinical project. The ancillary work is meant to be scientifically additive and connected to the parent project, using its participants, data collection, and/or biospecimen resources.
What is meant by an "ongoing clinical project" or "parent" study?
The parent study is an existing clinical project that is already active (for example, already enrolling participants or already collecting data and biospecimens). The ancillary study should be designed to fit alongside that parent study and take advantage of its infrastructure and resources.
Does this opportunity allow proposing a new clinical trial?
No. The announcement is designated "Clinical Trial Not Allowed," meaning applicants cannot propose a new clinical trial as the ancillary study itself.
What does "Clinical Trial Not Allowed" mean in practical terms?
It means the proposed ancillary study should not involve prospectively assigning human participants to an intervention or condition in order to evaluate effects on health-related outcomes. Instead, the work should rely on participants, measurements, clinical data, or biospecimens from an existing clinical project.
What kinds of research activities are typically supported under this mechanism?
Examples described for this type of opportunity include laboratory analyses of stored or newly collected biospecimens, additional biomarker assays, immunologic or genomic profiling, advanced imaging analyses, physiologic or pharmacodynamic assessments, and other mechanistic measurements that can be layered onto the parent study.
Can the ancillary study use newly collected biospecimens?
Yes. The description indicates support can include laboratory analyses of stored or newly collected biospecimens, as long as this fits within the framework of leveraging the ongoing clinical project and does not cross into proposing a new clinical trial.
How closely must the ancillary study be connected to the parent clinical project?
The ancillary study should be clearly connected to the parent project, scientifically additive (not duplicative), and realistically implementable within the timelines and operational constraints of the ongoing clinical work.
Does the ancillary study need to be hypothesis-driven?
Yes. Because this uses the R01 research project grant mechanism, the application is expected to propose a well-developed, hypothesis-driven ancillary study with clear aims, strong scientific rationale, and a feasible plan.
What is the funding mechanism for PAR-21-055?
The opportunity uses the NIH R01 research project grant mechanism.
What is the award ceiling mentioned for this opportunity?
The source data for the opportunity provides an award ceiling of $300,000, which signals a budget expectation or maximum as presented in that dataset. Applicants are still expected to follow the specific budget rules and guidance in the full announcement and NIH policies.
Is the expected number of awards stated?
No. The excerpted source data does not list an expected number of awards.
What is the CFDA number associated with this opportunity?
The opportunity is listed under CFDA number 93.846.
How is this program categorized?
It is categorized as a discretionary grant program and uses the grant funding instrument.
What was the closing date shown in the source data?
The original closing date shown in the source data is 2022-11-21.
When was the opportunity record created (per the provided data)?
The opportunity record creation date shown is 2020-10-22.
Could the opportunity have been reissued, updated, or replaced since the dates shown?
Yes. The information provided notes that NIH opportunities can be reissued, updated, or replaced over time, so applicants would typically verify current status and active receipt dates in the live NIH posting and related notices.
Which types of organizations are eligible to apply?
Eligibility is broad and includes: state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; public housing authorities and Indian housing authorities; Native American tribal organizations other than federally recognized tribal governments; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations other than small businesses; and small businesses.
Are minority-serving institutions and other designated institution types highlighted as eligible?
Yes. The opportunity explicitly highlights additional eligible applicant categories including Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal government agencies; regional organizations; and U.S. territories or possessions.
Are non-U.S. (foreign) organizations eligible to apply as the primary applicant?
No. Non-domestic (non-U.S.) entities (foreign organizations) and non-domestic (non-U.S.) foreign institutions are stated as not eligible to apply.
Are non-U.S. components of U.S. organizations eligible?
No. The opportunity states that non-domestic components of U.S. organizations are also not eligible to apply.
Are foreign components allowed in any form?
Yes. The description states that foreign components are allowed as defined in the NIH Grants Policy Statement. This generally means a U.S. applicant can include a foreign component when it is scientifically justified and appropriately managed and disclosed, even though a foreign institution cannot be the primary applicant.
What is the main advantage of proposing an ancillary study instead of a standalone project?
The opportunity is designed to support deeper mechanistic science by leveraging an active clinical project that is already enrolling participants and/or collecting data and biospecimens. This can make mechanistic research more efficient and feasible than creating a standalone study from scratch.
What are key features a competitive application should demonstrate (based on the description provided)?
Based on the provided description, a strong application would typically show that the mechanistic ancillary work is tightly integrated with the ongoing clinical project, provides high value for understanding disease processes or treatment responses, stays within the "no clinical trial" boundary, and can be completed with a realistic plan for coordination, data and specimen access, human subjects protections, and analytical rigor.
Can the ancillary study disrupt or change the operations of the parent clinical project?
The ancillary study is expected to fit alongside the parent clinical project without disrupting it and should be implementable within the timelines and operational constraints of the ongoing clinical work.
Is the ancillary study expected to be duplicative of the parent project?
No. The ancillary study should be scientifically additive and not duplicative of the parent project.
What kinds of mechanistic questions is this opportunity intended to address?
It is intended to support investigations into underlying mechanisms relevant to human health, described as biological, behavioral, or other mechanistic "how and why" questions that can be answered by leveraging the parent clinical project's participants, data, and/or biospecimens.
Browse more opportunities from the same category: Health
Next opportunity: FY 2021 Cooperative Endangered Species Conservation Fund (CESCF) Traditional Conservation Grants Program (Service Legacy Region 1)
Previous opportunity: Community Food Projects Program
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 055
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 055) also looked into and applied for these:
| Funding Opportunity |
|---|
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) Apply for PAR 21 054 Funding Number: PAR 21 054 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Improving Health Status and Human Capital in Senegal Apply for 72068521APS00001 Funding Number: 72068521APS00001 Agency: Senegal USAID-Dakar Category: Health Funding Amount: $88,000,000 |
| NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke (R25 - Clinical Trial Not Allowed) Apply for PAR 20 311 Funding Number: PAR 20 311 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Apply for PAR 21 040 Funding Number: PAR 21 040 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Treatments for Lewy Body Dementias--Exploratory Clinical Trial (U01 Clinical Trial Required) Apply for RFA NS 21 008 Funding Number: RFA NS 21 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Regional Technology Transfer Accelerator Hubs for IDeA States (STTR) (UT2 - Clinical Trial Not Allowed) Apply for RFA GM 21 001 Funding Number: RFA GM 21 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional) Apply for RFA MD 21 001 Funding Number: RFA MD 21 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial Not Allowed) Apply for RFA RM 21 007 Funding Number: RFA RM 21 007 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required) Apply for RFA MD 21 002 Funding Number: RFA MD 21 002 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Exploring the Scientific Value of Existing or New Sepsis Human Biospecimen Collections (R21/R33 - Clinical Trial Not Allowed) Apply for PAR 21 077 Funding Number: PAR 21 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) Apply for PAR 21 036 Funding Number: PAR 21 036 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required) Apply for PAR 21 045 Funding Number: PAR 21 045 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R43/R44 Clinical Trial Optional) Apply for RFA MH 21 112 Funding Number: RFA MH 21 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAAA Resource-Related Research Projects (R24 Clinical Trial Not Allowed) Apply for PAR 21 072 Funding Number: PAR 21 072 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed) Apply for PAR 21 053 Funding Number: PAR 21 053 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R34 Clinical Trial Optional) Apply for RFA MH 21 111 Funding Number: RFA MH 21 111 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service-Ready Tools for Identification, Prevention, and Treatment of Individuals at Risk for Suicide (R01 Clinical Trial Optional) Apply for RFA MH 21 110 Funding Number: RFA MH 21 110 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Social Drivers of Mental Illnesses in Low- and Middle-Income Countries: Mechanisms and Pathways of Interventions for Youth (R01 Clinical Trial Optional) Apply for RFA MH 21 160 Funding Number: RFA MH 21 160 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required) Apply for PAR 21 043 Funding Number: PAR 21 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional) Apply for RFA MH 21 105 Funding Number: RFA MH 21 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 055", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.